Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Vaccines

PUBLISHER: Grand View Research | PRODUCT CODE: 1771704

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1771704

Respiratory Syncytial Virus Vaccines Market Size, Share & Trends Analysis Report By Type (Passive Immunization, Preventive Vaccines), By Technology, By Targeted Population, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

RSV Vaccines Market Growth & Trends:

The global respiratory syncytial virusvaccines market size is expected to reach USD 28.39 billion by 2030, registering a CAGR of 42.17% from 2025 to 2030, according to a new report by Grand View Research, Inc. As populations age and comorbidities such as COPD, asthma, and diabetes become more prevalent, the demand for preventive measures like vaccination continues to rise. Regulatory approvals of RSV vaccines across multiple age groups have significantly expanded the addressable market. Furthermore, growing government support, including public immunization campaigns, has helped boost vaccination uptake and market penetration. The increasing global recognition of RSV as a serious public health threat underlines the importance of continued innovation and investment in this sector.

A key factor propelling market growth is the expansion of vaccine recommendations by public health authorities. In April 2025, the U.S. Advisory Committee on Immunization Practices (ACIP) voted to recommend RSV vaccines, including GSK's AREXVY, for adults aged 50-59 who are at elevated risk of severe RSV disease. This includes individuals with chronic conditions such as asthma, chronic obstructive pulmonary disease (COPD), diabetes, heart disease, and those residing in long-term care facilities. This recommendation builds upon ACIP's earlier vote in June 2024 to advise vaccination for all adults aged 75 and older, and for those aged 60-74 with underlying health risks. These policy expansions are critical in driving vaccine coverage and boosting the commercial viability of products like AREXVY, further energizing the RSV vaccine market.

Technological innovation and product differentiation are also vital forces shaping the RSV vaccine landscape. Breakthroughs in mRNA and adjuvanted vaccine platforms have improved efficacy, safety profiles, and delivery convenience. For example, Moderna's mRESVIA, approved in May 2024 for adults aged 60 and older, represents the company's second FDA-approved mRNA vaccine and highlights the momentum of mRNA technologies in infectious disease prevention. GSK's AREXVY leverages an adjuvanted formulation to enhance immune response in older adults, especially those with weakened immune systems. The availability of multiple vaccine options tailored to different population segments supports competition while broadening access and boosting market confidence in RSV vaccine efficacy.

Increased investments from both public and private sectors are accelerating the pace of clinical trials and regulatory approvals. Major pharmaceutical companies such as Pfizer, Moderna, GSK, and Merck are actively pursuing new indications and age groups through extensive Phase 3 trials. Pfizer continues to expand its RSV vaccine ABRYSVO into younger adult age groups. These developments are expected to intensify competition, improve product innovation, and lower costs over time, which is crucial for sustaining long-term market growth, particularly in emerging economies.

Additionally, partnerships with global health organizations and tiered pricing strategies will be key in expanding RSV vaccine access across low- and middle-income countries. As climate change and global mobility contribute to changes in RSV seasonality and transmission patterns, integrated surveillance and responsive vaccination policies will be increasingly important. With expanding recommendations and a strong innovation pipeline, the RSV vaccine market is poised for continued growth and public health impact.

Respiratory Syncytial Virus Vaccines Market Report Highlights:

  • In 2024, passive immunization led the market with a market share of 75.02%, primarily driven by advancements in monoclonal antibody (mAb) therapies.
  • The monoclonal antibodies (mAbs) segment secured the dominant market share in 2024. mAbs offer immediate passive immunity, making them ideal for protecting high-risk populations such as newborns and immunocompromised individuals.
  • The infants and children held the largest market share of 75.02% in 2024, due to the high disease burden and recent preventive breakthroughs. RSV is the leading cause of hospitalization in infants globally, prompting urgent demand for effective protective measures.
  • Hospital & retail pharmacies are expected to dominate the market in 2024 with share of 53.68% fueled by rising demand, vaccine accessibility, and expanding immunization programs.
  • North America holds a substantial share of the global RSV vaccine market, attributed to the high prevalence of RSV infections and advanced healthcare infrastructure.
  • The global RSV vaccines market is highly competitive, with key players such as AstraZeneca, Sanofi, GSK, Pfizer, Moderna, Icosavax, Meissa Vaccines, Codagenix, Blue Lake Biotechnology, and Merck, focusing on enhancing the vaccine.
Show more
Product Code: GVR-4-68040-625-1

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. RSV (Respiratory Syncytial Virus) Vaccines Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. RSV (Respiratory Syncytial Virus) Vaccines Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. RSV (Respiratory Syncytial Virus) Vaccines Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. RSV (Respiratory Syncytial Virus) Vaccines Market: Type Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Passive Immunization
    • 4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Preventive Vaccines
    • 4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. RSV (Respiratory Syncytial Virus) Vaccines Market: Technology Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. RSV (Respiratory Syncytial Virus) Vaccines Market: Technology Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Monoclonal Antibodies
    • 5.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Recombinant Protein + Adjuvant
    • 5.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. mRNA-Based Vaccine
    • 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Virus-Like Particle (VLP)
    • 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. RSV (Respiratory Syncytial Virus) Vaccines Market: Targeted Population Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. RSV (Respiratory Syncytial Virus) Vaccines Market: Targeted Population Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Adults
    • 6.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Infants and children
    • 6.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. RSV (Respiratory Syncytial Virus) Vaccines Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. RSV (Respiratory Syncytial Virus) Vaccines Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
  • 7.3. Hospital & Retail Pharmacies
    • 7.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Government Suppliers
    • 7.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Others
    • 7.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. RSV (Respiratory Syncytial Virus) Vaccines Market: Regional Estimates & Trend Analysis

  • 8.1. RSV (Respiratory Syncytial Virus) Vaccines Market Share, By Region, 2024 & 2030 (USD Million)
  • 8.2. North America
    • 8.2.1. North America RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Canada RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. UK RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Germany RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. France RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Italy RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Spain RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Sweden RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Norway RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Japan RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. China RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. India RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. Australia
      • 8.4.5.1. Australia RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6. South Korea
      • 8.4.6.1. South Korea RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Thailand RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Argentina
      • 8.5.3.1. Argentina RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. South Africa RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. South Africa RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. UAE RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Kuwait RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Heat Map Analysis
  • 9.4. Company Profiles
    • 9.4.1. AstraZeneca
      • 9.4.1.1. Participant's Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Recent Developments/ Strategic Initiatives
    • 9.4.2. Sanofi
      • 9.4.2.1. Participant's Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Recent Developments/ Strategic Initiatives
    • 9.4.3. GSK
      • 9.4.3.1. Participant's Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Recent Developments/ Strategic Initiatives
    • 9.4.4. Pfizer Inc.
      • 9.4.4.1. Participant's Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Recent Developments/ Strategic Initiatives
    • 9.4.5. Moderna
      • 9.4.5.1. Participant's Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Recent Developments/ Strategic Initiatives
    • 9.4.6. Icosavax
      • 9.4.6.1. Financial Performance
      • 9.4.6.2. Product Benchmarking
      • 9.4.6.3. Recent Developments/ Strategic Initiatives
    • 9.4.7. Meissa Vaccines
      • 9.4.7.1. Participant's Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Recent Developments/ Strategic Initiatives
    • 9.4.8. Codagenix
      • 9.4.8.1. Participant's Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Recent Developments/ Strategic Initiatives
    • 9.4.9. Blue Lake Biotechnology
      • 9.4.9.1. Participant's Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Recent Developments/ Strategic Initiatives
    • 9.4.10. Merck & Co., Inc.
      • 9.4.10.1. Participant's Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Recent Developments/ Strategic Initiatives
Show more
Product Code: GVR-4-68040-625-1

List of Tables

  • Table 1. List of abbreviation
  • Table 2. Global RSV (Respiratory Syncytial Virus) vaccines market, by region, 2018 - 2030 (USD Million)
  • Table 3. Global RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 4. Global RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 5. Global RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 6. Global RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7. North America RSV (Respiratory Syncytial Virus) vaccines market, by country, 2018 - 2030 (USD Million)
  • Table 8. North America RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 9. North America RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 10. North America RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 11. North America RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12. U.S. RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 13. U.S. RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 14. U.S. RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 15. U.S. RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16. Canada RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 17. Canada RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 18. Canada RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 19. Canada RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20. Mexico RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 21. Mexico RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 22. Mexico RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 23. Mexico RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24. Europe RSV (Respiratory Syncytial Virus) vaccines market, by country, 2018 - 2030 (USD Million)
  • Table 25. Europe RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 26. Europe RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 27. Europe RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 28. Europe RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 29. UK RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 30. UK RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 31. UK RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 32. UK RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33. Germany RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 34. Germany RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 35. Germany RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 36. Germany RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37. France RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 38. France RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 39. France RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 40. France RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41. Italy RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 42. Italy RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 43. Italy RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 44. Italy RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45. Spain RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 46. Spain RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 47. Spain RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 48. Spain RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49. Denmark RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 50. Denmark RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 51. Denmark RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 52. Denmark RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53. Sweden RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 54. Sweden RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 55. Sweden RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 56. Sweden RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57. Norway RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 58. Norway RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 59. Norway RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 60. Norway RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61. Asia Pacific RSV (Respiratory Syncytial Virus) vaccines market, by country, 2018 - 2030 (USD Million)
  • Table 62. Asia Pacific RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 63. Asia Pacific RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 64. Asia Pacific RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 65. Asia Pacific RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 66. Japan RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 67. Japan RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 68. Japan RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 69. Japan RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70. China RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 71. China RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 72. China RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 73. China RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74. India RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 75. India RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 76. India RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 77. India RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 78. Australia RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 79. Australia RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 80. Australia RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 81. Australia RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82. South Korea RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 83. South Korea RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 84. South Korea RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 85. South Korea RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 86. Thailand RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 87. Thailand RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 88. Thailand RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 89. Thailand RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90. Latin America RSV (Respiratory Syncytial Virus) vaccines market, by country, 2018 - 2030 (USD Million)
  • Table 91. Latin America RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 92. Latin America RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 93. Latin America RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 94. Latin America RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 95. Brazil RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 96. Brazil RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 97. Brazil RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 98. Brazil RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 99. Argentina RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 100. Argentina RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 101. Argentina RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 102. Argentina RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 103. MEA RSV (Respiratory Syncytial Virus) vaccines market, by country, 2018 - 2030 (USD Million)
  • Table 104. MEA RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 105. MEA RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 106. MEA RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 107. MEA RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 108. South Africa RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 109. South Africa RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 110. South Africa RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 111. South Africa RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 112. Saudi Arabia RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 113. Saudi Arabia RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 114. Saudi Arabia RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 115. Saudi Arabia RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 116. UAE RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 117. UAE RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 118. UAE RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 119. UAE RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 120. Kuwait RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 121. Kuwait RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 122. Kuwait RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 123. Kuwait RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 RSV (Respiratory Syncytial Virus) vaccines market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot-1
  • Fig. 14 Segment snapshot-2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Market trends & outlook
  • Fig. 17 Porter's five force analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 RSV (Respiratory Syncytial Virus) vaccines market: Product outlook key takeaways
  • Fig. 20 RSV (Respiratory Syncytial Virus) vaccines market: Type movement analysis
  • Fig. 21 Passive immunization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Preventive vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 RSV (Respiratory Syncytial Virus) vaccines market: Technology outlook key takeaways
  • Fig. 24 RSV (Respiratory Syncytial Virus) vaccines market: Technology movement analysis
  • Fig. 25 Monoclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Recombinant Protein + Adjuvant market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 mRNA-based vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 RSV (Respiratory Syncytial Virus) vaccines market: Targeted Population outlook key takeaways
  • Fig. 29 RSV (Respiratory Syncytial Virus) vaccines market: Targeted Population movement analysis
  • Fig. 30 Adults market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Infants and children market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 RSV (Respiratory Syncytial Virus) vaccines market: Distribution Channel outlook key takeaways
  • Fig. 33 RSV (Respiratory Syncytial Virus) vaccines market: Distribution Channel movement analysis
  • Fig. 34 Hospital & retail pharmacies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Government suppliers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Regional marketplace outlook, 2024 & 2030 (USD million)
  • Fig. 38 Regional marketplace: Key takeaways
  • Fig. 39 North America RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 US RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Canada RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 Mexico RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Europe RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 UK RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Germany RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 France RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Spain RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Italy RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Denmark RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Sweden RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Norway RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Asia Pacific RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Japan RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 China RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 India RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Australia RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 South Korea RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Thailand RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Market participant categorization
  • Fig. 78 RSV (Respiratory Syncytial Virus) vaccines market position analysis, 2024
  • Fig. 79 Strategic framework
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!